Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced the appointment of Eilon Elmalem as site head of its wholly owned subsidiary Scinai Biopharma Services’ Yavne CDMO facility, effective June 14, 2026. The appointment marks a significant step in the company's strategy to expand its contract development and manufacturing organization (CDMO) capabilities. Elmalem, who has served as an external consultant for the company over the past two years, brings more than two decades of biotechnology and pharmaceutical operations experience to the role. He will oversee site operations and engineering activities as Scinai continues to grow its CDMO platform.
The Yavne facility is a key asset for Scinai, which operates as a biopharmaceutical company focused on developing innovative immunology therapies. The company also advances a pipeline of therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. By strengthening its CDMO operations, Scinai aims to provide development and manufacturing services to other biotechnology and pharmaceutical companies, creating an additional revenue stream and supporting the broader biotech ecosystem.
Elmalem’s extensive background includes leadership roles in operations and engineering at several biotech and pharmaceutical firms. His previous consulting work with Scinai has given him deep familiarity with the company’s operations and strategic goals. The appointment is expected to drive efficiency and quality at the Yavne facility, which is poised to play a central role in Scinai’s growth plans.
Investors can find the latest news and updates relating to SCNI at the company’s newsroom at https://ibn.fm/SCNI. The full press release is available at https://ibn.fm/VLt3w.
